Welcome to our dedicated page for AIM ImmunoTech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.
No Rule 10b5-1 trading plan is reported for this transaction.
AIM ImmunoTech Inc. (AIM) reported that its CEO and President, Thomas K. Equels, purchased 11,000 shares of common stock on September 16, 2026, in an open-market or private transaction at $0.21 per share. Following this buy, he directly holds 102,822 common shares, and no Rule 10b5-1 trading plan is reported.
AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share. Following this buy, he directly owns 91,822 shares of AIM Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 5,900 shares of its Common Stock on September 14, 2026, in a purchase characterized as an open market or private transaction at $0.219 per share. Following this transaction, he holds 69,822 shares with direct ownership, and no Rule 10b5-1 trading plan is reported.
AIM ImmunoTech Inc. (AIM) entered into two exchange agreements with Streeterville Capital, LLC between September 8 and September 9, 2026, using corresponding partitioned promissory notes tied to a previously issued promissory note dated November 18, 2025. Under these agreements, approximately $400,000 of debt was converted into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. Stockholders had previously approved the conversion or other satisfaction of the promissory note pursuant to NYSE American Company Guide Sections 713(a) and 713(b) at a special meeting held on July 15, 2026. The exchange shares were or will be issued in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
AIM ImmunoTech Inc. (AIM) reports that on September 3 and 4, 2026 it entered into two exchange agreements with Streeterville Capital, LLC tied to an existing Promissory Note dated November 18, 2025. Under these agreements and related partitioned promissory notes, approximately $450,000 of debt was converted into 1,921,441 shares of common stock at an average conversion price of about $0.234 per share. Stockholders had previously approved the conversion or other satisfaction of this note at a special meeting on July 15, 2026 pursuant to NYSE American Company Guide Sections 713(a) and 713(b). The exchange shares were or will be issued in reliance on the Section 3(a)(9) exemption from Securities Act registration.
AIM ImmunoTech Inc. (AIM) entered into five exchange agreements with Streeterville Capital, LLC between August 31 and September 3, 2026 to address an existing promissory note dated February 16, 2024. Under these agreements, approximately $1,224,341 of the note was converted into 5,065,840 shares of common stock.
The exchanges were effected via corresponding partitioned promissory notes at an average conversion price of about $0.24 per share, and as of September 3, 2026 the promissory note was satisfied in full with no remaining amounts owed. Stockholders had previously approved the conversion or other satisfaction of this note on July 15, 2026 pursuant to NYSE American Company Guide Sections 713(a) and 713(b). The exchange shares were or will be issued under the Securities Act exemption in Section 3(a)(9) for exchanges with an existing security holder where no commission or other remuneration is paid for soliciting the exchange.
AIM ImmunoTech Inc. reported that CEO Thomas K. Equels authored a sponsor-supplied article on Breaking Defense titled “Biodefense is force protection: Ready today, prepared for tomorrow.” The piece argues that biodefense should be treated as military force protection and highlights the company’s drug Ampligen (rintatolimod) as a potential broad-spectrum early-onset and/or prophylactic antiviral for Ebola virus disease and coronaviruses, based on government-funded preclinical studies. The article cites 100% survival in one rintatolimod-treated mouse cohort versus 100% mortality in controls in an Ebola model and describes prior preclinical work in SARS-related coronaviruses. AIM emphasizes that these findings are preclinical proof-of-concept, not FDA approval or evidence of clinical efficacy, and includes extensive forward-looking statement and risk-factor cautions.
AIM ImmunoTech Inc. reported second-quarter 2026 results and progress on its lead drug Ampligen in metastatic pancreatic cancer. The company completed patient enrollment and Ampligen dosing in the Phase 2 DURIPANC study combining Ampligen with Imfinzi and engaged Thermo Fisher Scientific’s PPD business to support planned Phase 3 trial design. AIM highlighted prior Dutch Named Patient Program data where Ampligen achieved a median Overall Survival of 34.8 months versus 12.5 months for historical controls in a selected biomarker subset, and anticipates DURIPANC clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027.
Cash and cash equivalents were $9.9 million as of June 30, 2026, compared with approximately $3.0 million as of December 31, 2025, following multiple financing transactions and regaining full NYSE American listing compliance. For Q2 2026, research and development expenses were approximately $589,000 versus $1.2 million a year earlier, while general and administrative expenses rose to about $2.9 million from $1.5 million. Net loss was approximately $(3.8 million), or $(0.43) per share, compared with $(2.8 million), or $(3.68) per share, for Q2 2025. The company is also planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease.
AIM ImmunoTech Inc., an immuno‑pharma company developing Ampligen and Alferon, reported very limited Q2 2026 revenue of $26 thousand and an operating loss of $3.5 million, compared with a $2.6 million operating loss a year earlier. Net loss for the quarter was $3.8 million, and $6.8 million for the first half of 2026.
Cash and cash equivalents increased to $9.9 million at June 30, 2026 from $3.0 million at December 31, 2025, driven by $14.4 million of net cash provided by equity offerings and warrant exercises in the first six months. Total assets were $12.7 million, with stockholders’ equity improving to $7.7 million from a $9.8 million deficit.
Management states that recurring losses and operating cash outflows of $7.3 million for the first half raise substantial doubt about the company’s ability to continue as a going concern for at least one year. AIM continues to advance Ampligen, including a fully enrolled Phase 2 DURIPANC trial in metastatic pancreatic cancer and preparatory work for a potential Phase 3 study.